{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:22Z","timestamp":1790996182977,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.592487","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T06:02:26Z","timestamp":1605074546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art"],"prefix":"10.3389","volume":"10","author":[{"given":"Massimo","family":"Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Paviglianiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Memoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus","volume":"55","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current Use and Trends in Hematopoietic Cell Transplantation in the United States","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058059","article-title":"Bortezomib for myeloma \u2013 much ado about something","volume":"352","author":"Dispenzieri","year":"2005","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30105-8","article-title":"Daratumumab: a game changer in myeloma therapy","volume":"7","author":"Ludwig","year":"2020","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.788643","article-title":"Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma","volume":"22","author":"Martino","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000305","article-title":"Advances in delivery of ambulatory autologous stemcell transplantation for multiple myeloma","volume":"11","author":"Khouri","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.11","article-title":"Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies","volume":"15","author":"Meisenberg","year":"1997","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.126","article-title":"Randomized study of early hospital discharge following autologousblood SCT: medical outcomes and hospital costs","volume":"47","author":"Faucher","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200349","article-title":"etal. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma","volume":"5","author":"Ferrara","year":"2004","journal-title":"Hematol J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01073.x","article-title":"Outpatient high-dose melphalan in multiple myeloma patients","volume":"47","author":"Kassar","year":"2007","journal-title":"Transfusion"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4065\/83.10.1131","article-title":"etal. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802535098","article-title":"Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease","volume":"50","author":"Anastasia","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.978","article-title":"Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on aoutpatient basis","volume":"29","author":"Ferrara","year":"2011","journal-title":"Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.12.006","article-title":"Safetyand cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma","volume":"19","author":"Holbro","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.03.027","article-title":"Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study","volume":"20","author":"Martino","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.05.006","article-title":"Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma","volume":"15","author":"Paul","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.931952","article-title":"A home- care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study","volume":"56","author":"Martino","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.77","article-title":"Safety and cost-effectiveness of outpatient autologous transplantation for multiple myelomain Asia: single-center perspective from Singapore","volume":"52","author":"Abid","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12970","article-title":"Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"99","author":"Shah","year":"2017","journal-title":"Eur J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.619","article-title":"Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center","volume":"19","author":"Kodad","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.01.001","article-title":"Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma","author":"Yip","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.09.012","article-title":"Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma","volume":"93","author":"Gertz","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B23","unstructured":"MistichelliJ Diagnosis Related Groups (DRGs) and the Prospective Payment System: Forecasting Social Implications1984"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.79","article-title":"Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective","volume":"44","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1456-8","article-title":"Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation\u2013guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"91","author":"Weissinger","year":"2012","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00277-013-1872-4","article-title":"Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients","volume":"93","author":"Pi\u00f1ana","year":"2014","journal-title":"Ann Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.017","article-title":"Impactof Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation","volume":"21","author":"Satlin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12464","article-title":"The role of primary antifungal prophylaxis in patients with haematological malignancies","author":"Pagano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B30","unstructured":"Clinical Practice Guidelines in Oncology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer Oxf Engl"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00736.x","article-title":"Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients","volume":"77","author":"Martino","year":"2006","journal-title":"Eur J Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1399-0012.2011.01532.x","article-title":"Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide","volume":"26","author":"Ziakas","year":"2012","journal-title":"Clin Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03901-w","article-title":"A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant","volume":"99","author":"Martino","year":"2020","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219865303","article-title":"Antimicrobial de-escalation in adult hematopoietic cell transplantation recipients with febrile neutropenia of unknown origin","volume":"26","author":"Petteys","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.02.003","article-title":"Work-up for Fever During Neutropenia for Both the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient","volume":"33","author":"Satyanarayana","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0811-y","article-title":"Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT). Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease WorkingParty survey","author":"Verlinden","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009031","article-title":"Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event","volume":"3","author":"Rivas-Ruiz","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-018-5054-6","article-title":"Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis","volume":"18","author":"Owattanapanich","year":"2018","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.06.001","article-title":"Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation","volume":"23","author":"Obiozor","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702534","article-title":"A comparison of inpatient and outpatient ASCT","volume":"26","author":"Summers","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.021","article-title":"etal. A Comssparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model","volume":"24","author":"Martino","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1188\/05.ONF.57-67","article-title":"Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation","volume":"32","author":"Schulmeister","year":"2005","journal-title":"Oncol Nurs Forum"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.164","article-title":"A scoping review of caregiver burden during allogeneic HSCT: lessons learnedand future directions","volume":"51","author":"Applebaum","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.208","article-title":"Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study","volume":"48","author":"Foster","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.2000.83005.x","article-title":"Caregiver responses and needs. An ambulatory bone marrow transplant model","volume":"8","author":"Grimm","year":"2000","journal-title":"Cancer Pract"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e31820a592d","article-title":"Informal caregivers of hematopoietic cell transplant patients: a review and recommendations for interventions and research","volume":"34","author":"Gemmill","year":"2011","journal-title":"Cancer Nurs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1962","article-title":"The experience of caregivers of hematological cancerpatients undergoing a hematopoietic stem cell transplant: a comprehensiveliterature review","volume":"20","author":"Beattie","year":"2011","journal-title":"Psychooncology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1300\/J077v24n03_03","article-title":"Explaining family caregiver role strain following autologous blood and marrow transplantation","volume":"24","author":"Eldredge","year":"2006","journal-title":"J Psychosoc Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1188\/04.ONF.1161-1169","article-title":"Psychological distress, fatigue, burden of care, and quality of life in primary caregivers of patients with breast cancer undergoing autologous bone marrow transplantation","volume":"31","author":"Gaston-Johansson","year":"2004","journal-title":"Oncol Nurs Forum"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.015","article-title":"Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients","volume":"24","author":"Jamani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32680","article-title":"Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial","volume":"126","author":"El-Jawahri","year":"2020","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701191","article-title":"Reduced charges and costs associated with outpatient autologous stem cell transplantation","volume":"21","author":"Meisenberg","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4238","article-title":"Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies","volume":"24","author":"Fern\u00e1ndez-Avil\u00e9s","year":"2006","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.09.003","article-title":"Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis","volume":"30","author":"Ghatnekar","year":"2008","journal-title":"Clin Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216639753","article-title":"Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment","volume":"23","author":"Clemmons","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"B58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5465\/amr.1986.4282622","article-title":"Diagnosis related groups: product line management within hospitals","volume":"11","author":"Fetter","year":"1986","journal-title":"Acad Manage Rev"},{"key":"B59","article-title":"Applying the ABCs in provider organizations","volume":"66","author":"Pandey","year":"2012","journal-title":"Healthc Financ Manage"},{"key":"B60","article-title":"The promise\u2013and peril\u2013of integrated cost systems","volume":"76","author":"Cooper","year":"1998","journal-title":"Harv Bus Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.018","article-title":"etal. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model","volume":"17","author":"Martino","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.772","article-title":"etal. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings","volume":"26","author":"Dunavin","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.592487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T23:40:41Z","timestamp":1618357241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.592487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":62,"alternative-id":["10.3389\/fonc.2020.592487"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.592487","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"article-number":"592487"}}